Up to date on July ninth, 2026 by Nathan Parsh
Becton, Dickinson & Firm (BDX) has elevated its dividend for 54 consecutive years, and because of this, it lately joined the unique record of Dividend Kings.
The Dividend Kings have raised dividend payouts for not less than 50 consecutive years.
You possibly can obtain the total record of Dividend Kings, plus vital monetary metrics corresponding to dividend yields and price-to-earnings ratios, by clicking on the hyperlink beneath:
You possibly can see all 58 Dividend Kings right here.
BDX has maintained its lengthy historical past of dividend will increase because of its superior place within the business. Its aggressive benefits have fueled the corporate’s long-term progress.
As we see the potential for continued progress within the healthcare business, BDX ought to proceed to extend its dividend annually.
This text will focus on BDX’s enterprise mannequin, progress catalysts, and anticipated returns.
Enterprise Overview
Becton, Dickinson & Firm is a worldwide chief within the medical provide business. Based in 1897, it operates in 190 international locations and generates annual gross sales of virtually $22billion. Practically half of the corporate’s income comes from exterior the U.S. BDX is valued at $41 billion.
The corporate operates 4 segments, together with Medical Necessities, Linked Care, BioPharma Methods, and Interventional.
On Could seventh, 2026, BDX launched earnings outcomes for the second quarter of fiscal 12 months 2026.
Supply: Investor Presentation
For the quarter, income grew 5.2% to $4.7 billion, which was $30 million higher than anticipated. Adjusted earnings-per-share from persevering with operations equaled $2.90, which was up from $2.79 within the prior 12 months and was $0.13 forward of estimates.
Medical Necessities grew 4.7% to $1.65 billion as features in U.S. Vascular Entry Administration and the BD Vacutainer portfolio had been solely partially offset by gross sales weak point in China. Linked Care was up 4.9% to $1.12 billion as a consequence of energy in Good Restoration and modest progress in U.S. Infusion. BioPharma was increased by 2.5% to $575 million as double-digit progress in Biologics was offset by decrease demand for vaccines. Interventional elevated 7.3% to $1.36 billion as a consequence of increased demand for Pure Wick, An infection Prevention, and the Rotarex Atherectomy System.
BDX supplied an up to date outlook for the fiscal 12 months as effectively.
Supply: Investor Presentation
The corporate now expects adjusted earnings-per-share in a spread of $12.52 to $12.72 for the fiscal 12 months, up from $12.35 to $12.65 beforehand. On the midpoint, adjusted EPS is projected to say no 12.4% for FY 2026. This decline can largely be defined by the separation of the corporate’s Biosciences and Diagnostic Options enterprise. Adjusting for this, the midpoint would symbolize 6.1% progress from FY 2025.
The corporate’s acquisition technique and innovation initiatives are noteworthy. BDX accomplished its $4.2 billion acquisition of Edwards Lifesciences’ Essential Care Product Group in September of 2024, bolstering its portfolio in superior monitoring know-how.
Lately, BDX secured FDA approval for its Life Sciences division to gather self-collected cervical most cancers screening samples in healthcare settings, thereby enhancing its diagnostic capabilities. Moreover, BDX expanded its single-cell analysis choices by launching the BD Rhapsody™ ATAC-Seq Assay. These strategic strikes align with BD’s targets underneath its BD X2025 technique, as famous by CEO Tom Polen, who highlighted the corporate’s drive towards innovation and management within the MedTech sector.
Progress Prospects
Healthcare shares like BDX are usually bought for his or her regular long-term progress. BDX is not any exception; the corporate has grown its earnings per share by 5.9% per 12 months over the previous decade.
Going ahead, we count on the corporate to publish 5% annual EPS progress fee over the following 5 years. This progress will likely be pushed primarily by the growing older U.S. inhabitants, which is anticipated to proceed rising demand for healthcare provides sooner or later.
U.S. well being expenditures are anticipated to complete greater than $6 trillion in 2026 and rise to $9 trillion in 2034, representing a 50% improve over this era.
This needs to be a broad tailwind from which main healthcare producers, corresponding to BDX, will profit.
BDX continues investing closely in product innovation, which is important to the corporate’s long-term progress targets.
Becton, Dickinson & Firm has aggressively added to its core enterprise. This contains the corporate’s $24 billion acquisition of Bard in 2017, its $1.525 billion buy of pharmacy automation options supplier Parata Methods in 2022, and its $4+ billion acquisition of Edwards Lifesciences’ Essential Care Product Group, amongst many others.
Additional acquisitions and share repurchases over the long run are more likely to result in further progress sooner or later.
Moreover, BDX accomplished its deliberate separation of its Biosciences and Diagnostic Options enterprise, which was then mixed with Waters Company (WAT), throughout the latest quarter. The remaining companies for BDX will likely be a pure-play medical know-how firm that has main positions in lots of massive and rising end-markets. The Biosciences and Diagnostic Options enterprise will even be a frontrunner in its respective areas of operation, with annual gross sales exceeding $3 billion. Recurring income represents greater than 80% of this complete. The separation was accomplished on February ninth, 2026.
Aggressive Benefits & Recession Efficiency
Becton, Dickinson & Firm has important aggressive benefits, together with scale and an unlimited patent portfolio. These benefits are as a consequence of excessive funding spending.
BDX spends over $1.0 billion annually on analysis and improvement. This funding is important to the corporate’s means to generate long-term progress and keep its business management.
It’s clear that its R&D spending has paid off, as the corporate possesses over 29,000 lively patents.
These aggressive benefits allow the corporate to realize constant progress, even throughout financial downturns.
Becton, Dickinson & Firm steadily grew earnings throughout the Nice Recession. Becton Dickinson’s earnings-per-share throughout the recession are as follows:
- 2007 earnings-per-share of $3.84
- 2008 earnings-per-share of $4.46 (16% improve)
- 2009 earnings-per-share of $4.95 (11% improve)
- 2010 earnings-per-share of $4.94 (0.2% decline)
Becton, Dickinson & Firm generated double-digit earnings progress in 2008 and 2009, throughout the worst years of the recession. It took a small step again in 2010 however continued to develop within the years since, together with the financial restoration.
The flexibility to constantly develop earnings annually throughout the Nice Recession, arguably the worst financial downturn in many years, is extraordinarily spectacular.
The corporate continued to carry out effectively in 2020, regardless of the coronavirus pandemic inflicting the U.S. financial system to enter a recession. BDX remained extremely worthwhile throughout this era and continued its streak of dividend will increase.
The explanation for its recession resilience is that healthcare sufferers want medical provides whatever the state of the broader financial system. This helps keep regular demand from 12 months to 12 months.
Valuation & Anticipated Returns
We count on BDX to generate earnings per share of $12.62 this 12 months. Because of this, the inventory is at the moment buying and selling at a price-to-earnings ratio of 11.9.
We take into account 19.0 to be a valuation for this inventory, which is barely beneath the 10-year common a number of.
Because of this, we view BDX inventory as undervalued proper now.
If the P/E a number of will increase from 11.9 to 19.0 over the following 5 years, shareholder returns would improve by 9.8% yearly.
Moreover, dividend and earnings-per-share progress will improve shareholder returns. BDX shares at the moment yield 2.8%, which is likely one of the highest yields within the final decade. We count on 5% annual EPS progress over the following 5 years.
Subsequently, BDX inventory is anticipated to generate annual returns of 17.1% over the following 5 years.
Closing Ideas
Becton, Dickinson & Firm is likely one of the latest members of the unique Dividend Kings record. Because of its main place within the healthcare business, the corporate has maintained a dividend progress streak of over 50 consecutive years.
Due to the growing older U.S. inhabitants, the corporate is anticipated to learn from this long-term progress catalyst, which ought to allow BDX to proceed elevating its dividend for a few years to return.
BDX is at the moment buying and selling at a valuation considerably beneath our goal. We see the potential for annual returns of greater than 17% over the following 5 years, making BDX inventory a purchase this present day.
The next articles comprise shares with very lengthy dividend or company histories, ripe for choice for dividend progress buyers:
Thanks for studying this text. Please ship any suggestions, corrections, or inquiries to [email protected].
